ClinicalTrials.gg
CompletedNCT02426918Updated Nov 13, 2019Results posted

Study of Debio 1450 for Bacterial Skin Infections

A Phase 2 interventional study of Debio 1450 IV and Debio 1450 Oral in Bacterial Infections, sponsored by Debiopharm International SA. Completed at 22 sites in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-11-13.

Sponsored by Debiopharm International SA (part of Debiopharm) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
330
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 181 studies in Bacterial Infections with a site in United States — 12 open to participants now, 15 under way, 2 of them phase 3. Bacterial Infections · United States.

Enrollment
31st of 151
330 · median 62
Started
2015
with 8 others
Phase 2
26 of 181
1 open now
Registered
91st of 181
by date
Lead sponsor
3 of 181
Debiopharm International SA

Among the 181 studies in Bacterial Infections with a site in United States, this one is the 31st largest by enrollment of the 151 interventional ones that give a count, is one of 9 that started in 2015, is one of 26 in phase 2, and was the 91st registered.

Bacterial Infections

585 studies on the registry are indexed under Bacterial Infections; 84 are open to participants now.

Browse Bacterial Infections studies →

Open to participants now

12 of the 181 studies in Bacterial Infections with a site in United States are open now. Recruiting first, the newest first:

7 more — sign in →

All 12 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 57 Bacterial Infections studies recruiting now, 38 (67%) set no upper age limit and 14 (25%) stop at 75 or younger; 19 take children under 18; 6 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 181 studies in Bacterial Infections with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the efficacy of 2 different doses of intravenous and oral Debio 1450 compared with intravenous vancomycin and oral linezolid in the treatment of patients with staphylococcal ABSSSI.

03

Conditions studied

  • Bacterial Infections

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has clinically documented infection of the skin or skin structure suspected or documented to be caused by a staphylococcal pathogen
  • Meets other protocol-specified criteria for qualification and
  • Is willing and able to remain confined in the study unit for the entire duration of each treatment period and comply with restrictions related to food, drink and medications
  • Voluntarily consents to participate and provides written prior to any protocol-specific procedures

Exclusion criteria

Exclusion Criteria:

  • Has history or current use of over-the-counter medications, dietary supplements, or drugs (including nicotine and alcohol) outside protocol-specified parameters
  • Has signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise:

    1. the safety or well-being of the participant or study staff;
    2. the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding);
    3. the analysis of results
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Debio 1450 320/480 mg

    After 2 doses of Debio 1450 IV (intravenous) therapy, the Debio 1450 320/480 mg daily dose group receives 240 mg Debio 1450 Oral + Linezolid Placebo twice daily (BID).

    Drug: Debio 1450 IV · Drug: Debio 1450 Oral · Drug: Linezolid Placebo

  • Experimental
    Debio 1450 160/240 mg

    After 2 doses of Debio 1450 IV therapy, the Debio 1450 160/240 mg daily dose group receives 120 mg Debio 1450 Oral + Debio 1450 Oral Placebo + Linezolid Placebo BID.

    Drug: Debio 1450 IV · Drug: Debio 1450 Oral · Drug: Debio 1450 Oral Placebo · Drug: Linezolid Placebo

  • Placebo comparator
    Placebo

    After 2 doses of Vancomycin IV, the Placebo comparator group receives Debio 1450 Oral Placebo + Linezolid 600 mg BID.

    Drug: Linezolid · Drug: Debio 1450 Oral Placebo · Drug: Vancomycin IV

Interventions

  • Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).

  • Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).

  • DrugLinezolid

    Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.

  • DrugDebio 1450 Oral Placebo

    Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.

  • DrugLinezolid Placebo

    Linezolid placebo will be supplied as film-coated compressed tablets.

  • DrugVancomycin IV

    Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.

06

What researchers measure

Primary outcomes

  1. Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator

    ECRR was defined as the percentage of responders to treatment at 48 to 72 hours from randomization. Responders were the participants who showed greater than or equal to (≥) 20% reduction in area of the primary lesion involving erythema, edema, or induration of the primary ABSSSI lesion (as assessed by the ruler method) at 48 to 72 hours compared to baseline.

    Time frame: At 48 to 72 hours from randomization (Day 4)

Secondary outcomes

  1. Clinical Success Rate: Percentage of Participants Assessed by the Investigator as Responders at 48 to 72 Hours From Randomization, at End of Treatment (EOT) and Short-term Follow-up (STFU)

    The Investigator Assessment of Clinical Outcome (IACO) of treatment was assessed for each participant as success or failure at 48 to 72 hours after randomization at EOT and STFU visits. Clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms, or complications attributable to ABSSSI such that no further antibiotic therapy is required for treatment of original site of infection. Clinical failure was requirement for additional antibiotic therapy for treatment of the original site of infection or incision and drainage of ABSSSI site that was not both anticipated and completed within a 48- to 72-hour window following randomization, or unplanned major surgical intervention required due to failure of study medication or development of osteomyelitis after baseline. Participants who met both success criteria and none of failure criteria were considered as a clinical success for IACO.

    Time frame: 48 to 72 hours after randomization (Day 4), EOT (Day 12) and STFU (Day 19)

  2. Clinical Success Rate: Percentage of Participants Assessed by the Sponsor as Responders After 7 to 10 Days of Treatment at EOT and STFU

    The Sponsor's Assessment of Clinical Outcome was obtained at EOT and STFU visits based on IACO and additional criteria. Sponsor assessed participants as clinical failure if they required non-study or rescue antibiotics due to lack of efficacy after at least 48 hours from randomization or experienced drug-related serious adverse events (SAEs) or discontinuation of study medication for drug-related AEs or required antibiotic therapy for longer than 10 days or had the need for unplanned surgical intervention \>48 hours after randomization. As per IACO, clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms or complications. Clinical failure was requirement for additional antibiotic therapy or incision and drainage of ABSSSI site or unplanned major surgical intervention or development of osteomyelitis.

    Time frame: EOT (Day 12) and STFU (Day 19)

  3. Percentage of Participants With a Composite Assessment of Clinical Outcome (CACO) of Success

    CACO of treatment was determined as a combined outcome of early response to treatment (at 48 to 72 hours from randomization) and IACO at the STFU visit. Participants had a CACO of success if they met both of the following criteria: An early response to treatment (at 48 to 72 hours from randomization) (ECR = responder) and a clinical outcome of success at the STFU visit (7 to 14 days after EOT) based on IACO (IACO = success).

    Time frame: 48 to 72 hours after randomization (Day 4) and STFU (Day 19)

  4. Percentage of Participants Who Showed Microbiological Evidence of Cure 48 to 72 Hours From Randomization, EOT, and STFU

    The microbiological outcome was assessed by the sponsor at 48 to 72 hours from randomization, EOT and STFU. It was based on blood and skin lesion identification results from baseline samples and skin lesion identification results from baseline samples and skin lesion identification results from follow-up samples as well as on, molecular typing results, and the IACO. Microbiological eradication rate was defined as proportion of participants with 'Documented Eradication' (absence of baseline pathogen(s) in follow-up cultures of the original site of infection.) or 'Presumed Eradication' (no material available for culture and an IACO of 'Success') in relation to the total number of participants in the respective treatment group.

    Time frame: 48 to 72 hours after randomization (Day 4), EOT (Day 12) and STFU (Day 19)

07

Results

Posted Nov 13, 2019

Participant flow

Participants took part in the study in the United States, from 14 May 2015 to 12 September 2016. Of the 505 participants screened, 175 discontinued from the study prior to randomization and 330 were randomized.

Participant flow — Overall Study
MilestoneDebio 1450 80 mg (Milligrams)/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
Started110109111
Safety population110107107
Completed939097
Not completed171914
Withdrew: Adverse event220
Withdrew: Physician decision111
Withdrew: Withdrawal by subject554
Withdrew: Other9119

Outcome measures

PrimaryEarly Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator

ECRR was defined as the percentage of responders to treatment at 48 to 72 hours from randomization. Responders were the participants who showed greater than or equal to (≥) 20% reduction in area of the primary lesion involving erythema, edema, or induration of the primary ABSSSI lesion (as assessed by the ruler method) at 48 to 72 hours compared to baseline.

Time frame:
At 48 to 72 hours from randomization (Day 4)
Reported as:
Number · percentage of participants
Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator
percentage of participantsDebio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
Early Clinical Response Rate (ECRR): Percentage of Responders to Treatment at 48 to 72 Hours From Randomization as Assessed by the Investigator94.690.191.1
Statistical analysis
  • Debio 1450 80 mg/120 mg BID vs Vancomycin/Linezolid BID · Risk difference (rd): -4.2 · 95% CI -11.42 to 3.00
  • Debio 1450 160 mg/240 mg BID vs Vancomycin/Linezolid BID · Risk difference (rd): 0.0 · 95% CI -8.32 to 8.38
SecondaryClinical Success Rate: Percentage of Participants Assessed by the Investigator as Responders at 48 to 72 Hours From Randomization, at End of Treatment (EOT) and Short-term Follow-up (STFU)

The Investigator Assessment of Clinical Outcome (IACO) of treatment was assessed for each participant as success or failure at 48 to 72 hours after randomization at EOT and STFU visits. Clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms, or complications attributable to ABSSSI such that no further antibiotic therapy is required for treatment of original site of infection. Clinical failure was requirement for additional antibiotic therapy for treatment of the original site of infection or incision and drainage of ABSSSI site that was not both anticipated and completed within a 48- to 72-hour window following randomization, or unplanned major surgical intervention required due to failure of study medication or development of osteomyelitis after baseline. Participants who met both success criteria and none of failure criteria were considered as a clinical success for IACO.

Time frame:
48 to 72 hours after randomization (Day 4), EOT (Day 12) and STFU (Day 19)
Reported as:
Number · percentage of participants
Clinical Success Rate: Percentage of Participants Assessed by the Investigator as Responders at 48 to 72 Hours From Randomization, at End of Treatment (EOT) and Short-term Follow-up (STFU)
percentage of participantsDebio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
48 to 72 hours after randomization83.781.386.1
EOT92.487.992.1
STFU84.883.592.1
SecondaryClinical Success Rate: Percentage of Participants Assessed by the Sponsor as Responders After 7 to 10 Days of Treatment at EOT and STFU

The Sponsor's Assessment of Clinical Outcome was obtained at EOT and STFU visits based on IACO and additional criteria. Sponsor assessed participants as clinical failure if they required non-study or rescue antibiotics due to lack of efficacy after at least 48 hours from randomization or experienced drug-related serious adverse events (SAEs) or discontinuation of study medication for drug-related AEs or required antibiotic therapy for longer than 10 days or had the need for unplanned surgical intervention \>48 hours after randomization. As per IACO, clinical success was resolution or near resolution of most disease-specific signs and symptoms and no new signs, symptoms or complications. Clinical failure was requirement for additional antibiotic therapy or incision and drainage of ABSSSI site or unplanned major surgical intervention or development of osteomyelitis.

Time frame:
EOT (Day 12) and STFU (Day 19)
Reported as:
Number · percentage of participants
Clinical Success Rate: Percentage of Participants Assessed by the Sponsor as Responders After 7 to 10 Days of Treatment at EOT and STFU
percentage of participantsDebio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
EOT89.186.890.1
STFU81.581.390.1
SecondaryPercentage of Participants With a Composite Assessment of Clinical Outcome (CACO) of Success

CACO of treatment was determined as a combined outcome of early response to treatment (at 48 to 72 hours from randomization) and IACO at the STFU visit. Participants had a CACO of success if they met both of the following criteria: An early response to treatment (at 48 to 72 hours from randomization) (ECR = responder) and a clinical outcome of success at the STFU visit (7 to 14 days after EOT) based on IACO (IACO = success).

Time frame:
48 to 72 hours after randomization (Day 4) and STFU (Day 19)
Reported as:
Number · percentage of participants
Percentage of Participants With a Composite Assessment of Clinical Outcome (CACO) of Success
percentage of participantsDebio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
Percentage of Participants With a Composite Assessment of Clinical Outcome (CACO) of Success83.781.388.1
SecondaryPercentage of Participants Who Showed Microbiological Evidence of Cure 48 to 72 Hours From Randomization, EOT, and STFU

The microbiological outcome was assessed by the sponsor at 48 to 72 hours from randomization, EOT and STFU. It was based on blood and skin lesion identification results from baseline samples and skin lesion identification results from baseline samples and skin lesion identification results from follow-up samples as well as on, molecular typing results, and the IACO. Microbiological eradication rate was defined as proportion of participants with 'Documented Eradication' (absence of baseline pathogen(s) in follow-up cultures of the original site of infection.) or 'Presumed Eradication' (no material available for culture and an IACO of 'Success') in relation to the total number of participants in the respective treatment group.

Time frame:
48 to 72 hours after randomization (Day 4), EOT (Day 12) and STFU (Day 19)
Reported as:
Number · percentage of participants
Percentage of Participants Who Showed Microbiological Evidence of Cure 48 to 72 Hours From Randomization, EOT, and STFU
percentage of participantsDebio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
48 to 72 hours after randomization72.869.275.2
EOT92.486.891.1
STFU84.883.591.1

Adverse events

Collected over 21 days after EOT (Day 33). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Debio 1450 80 mg/120 mg BID—2/110 (1.8%)18/110 (16.4%)
Debio 1450 160 mg/240 mg BID—1/107 (0.9%)29/107 (27.1%)
Vancomycin/Linezolid BID—1/107 (0.9%)20/107 (18.7%)
Most frequent serious events
Most frequent serious events
EventDebio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
Skin infectionInfections and infestations2/1100/1070/107
CellulitisInfections and infestations0/1100/1071/107
OverdoseInjury, poisoning and procedural complications0/1101/1070/107
Most frequent other events
Most frequent other events
EventDebio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BID
HeadacheNervous system disorders10/11018/1079/107
NauseaGastrointestinal disorders7/1109/1077/107
DiarrhoeaGastrointestinal disorders3/1103/1076/107
VomitingGastrointestinal disorders1/1106/1072/107
AbscessInfections and infestations3/1106/1070/107

Baseline characteristics

Intent-to-Treat Population (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(years)Debio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BIDTotal
Mean43.9 ± 11.7142.8 ± 11.7244.8 ± 10.5743.8 ± 11.34
Sex: Female, Male
Sex: Female, Male(Participants)Debio 1450 80 mg/120 mg BIDDebio 1450 160 mg/240 mg BIDVancomycin/Linezolid BIDTotal
Female363532103
Male747479227
08

Study locations

22 sites
  • Dream Team Clinical Research, LLC
    Anaheim, California 91776, United States
  • Physician Alliance Research Center
    Anaheim, California 92804, United States
  • Southbay Pharma Research
    Buena Park, California 90620, United States
  • eStudySite - Chula Vista
    Chula Vista, California 91911, United States
  • eStudySite - La Mesa
    La Mesa, California 91942, United States
  • Long Beach Clinical Trials LLC
    Long Beach, California 90806, United States
  • Alliance Research
    Long Beach, California 90813, United States
  • Central Valley Research, LLC
    Modesto, California 95350, United States
  • eStudySite - Oceanside
    Oceanside, California 92056, United States
  • Olive View - UCLA Medical Center
    Sylmar, California 91342, United States
  • Shands Burn Center at the University of Florida
    Gainesville, Florida 32610, United States
  • Central Florida Internists
    Orlando, Florida 32811, United States
  • Triple O Research Institute
    West Palm Beach, Florida 33401, United States
  • Columbus Regional Research
    Columbus, Georgia 31904, United States
  • Beaumont Infectious Disease Services
    Royal Oak, Michigan 48073, United States
  • Mercury Street Medical Group PLLC
    Butte, Montana 59701, United States
  • eStudySite - Las Vegas
    Las Vegas, Nevada 89109, United States
  • South Jersey Infectious Disease
    Somers Point, New Jersey 08244, United States
  • Holy Name Medical Center
    Teaneck, New Jersey 07666, United States
  • ID Clinical Research, Ltd.
    Toledo, Ohio 43608, United States
  • East Montgomery County Clinic
    Houston, Texas 77070, United States
  • Tidwell Medical Center
    Splendora, Texas 77372, United States
09

References and documents

Publications

  • Wittke F, Vincent C, Chen J, Heller B, Kabler H, Overcash JS, Leylavergne F, Dieppois G. Afabicin, a First-in-Class Antistaphylococcal Antibiotic, in the Treatment of Acute Bacterial Skin and Skin Structure Infections: Clinical Noninferiority to Vancomycin/Linezolid. Antimicrob Agents Chemother. 2020 Sep 21;64(10):e00250-20. doi: 10.1128/AAC.00250-20. Print 2020 Sep 21. PubMed 32747361 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2015, a primary completion of Aug 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2019, 3 years 3 months after primary completion. A results delay was requested in Aug 2017.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2015
First posted
Apr 27, 2015
Start
May 2015
Primary completionActual
Aug 2016
CompletionActual
Sep 2016
Results delay requested
Aug 21, 2017
Results first posted
Nov 13, 2019
Last update
Nov 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02426918
Responsible party
Sponsor
First posted
Apr 27, 2015
Start date
May 2015
Primary completion
Aug 2016
Completion
Sep 2016
Results posted
Nov 13, 2019
Last update
Nov 13, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Afabicin

Start the discussion